Can a cancer drug beat steroids for brain radiation injury?
NCT ID NCT06888817
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares bevacizumab (Avastin) to standard steroid treatment (dexamethasone) as the first therapy for people with brain radiation necrosis—a side effect of radiation therapy for brain tumors. About 408 participants with high-grade glioma or brain metastases will be randomly assigned to one of the two treatments. The goal is to see which better improves daily function and reduces symptoms, while also being cost-effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (Avastin)
What this could lead to
If it works, this could provide a more effective and safer first-line treatment for brain radiation necrosis, reducing reliance on steroids and improving quality of life.
What could go wrong
This is a phase 3 trial, but it's open-label (not blinded), which can introduce bias. Bevacizumab also has known risks like bleeding and high blood pressure, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIATION NECROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam University Medical Centers, location VUmc and AMC
RECRUITINGAmsterdam, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Haaglanden Medical Center
RECRUITINGThe Hague, 2262 BA Leidschendam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Leiden University Medical Center
RECRUITINGLeiden, 2333 ZA Leiden, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Netherlands Cancer Institute - Antoni van Leeuwenhoek
RECRUITINGAmsterdam, 1066 CX Amsterdam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Utrecht
RECRUITINGUtrecht, 3584 CX Utrecht, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact